Search Results
Results found for "Omass Therapeutics"
- Dr. Paul Insel: Rethinking COVID-19 Pathobiology Through GPCR Signaling | Dr. GPCR Ecosystem
The therapeutic logic that follows is less about attacking the virus and more about rebalancing a GPCR-driven Dry-lab pharmacology and what becomes possible when wet-lab work stops GPCR density and tissue-specific therapeutic The review was accepted at Clinical Pharmacology and Therapeutics within weeks. If the virus disrupts one arm of this receptor-peptide system, the therapeutic question stops being "
- Dr. Aurélien Rizk | Dr. GPCR Ecosystem
the company's ability to predict the residence time of a ligand and its potential correlation with a therapeutic Therapeutic Effect and Receptor Interactions Aurelien Rizk and Yamina had a detailed discussion about the importance of gaining more information about the therapeutic effect in patients or animals and the They also shared their preference for small molecule therapies over protein therapeutics.
- Dr. Bryan Roth: Inside the DARPA Bet on a Non-Psychedelic Psychedelic | Dr. GPCR Ecosystem
The therapeutic mechanism, however, is inseparable from the psychedelic experience itself, and not every questions in current GPCR pharmacology: can biased signaling at the serotonin 2A receptor decouple the therapeutic What you usually can't do is know which pathway, in which disease, will actually be therapeutic. The premise: psilocybin's therapeutic effect on depression is now well documented, but it is locked to
- How Lipid Rafts Organize GPCR Signaling | Dr. GPCR Ecosystem
Keyvan Sedaghat discussing how GPCR function is shaped by lipid raft compartmentalization, the expanding therapeutic efficacy and diagnostic innovation What the functional diversity of bitter taste receptors means for novel therapeutic
- Yao Lu (Jackie) | Dr. GPCR Ecosystem
molecular explanation of small molecules for their pre-clinical efficacy and to support the design of novel therapeutics
- Celtarys Research | Dr. GPCR Ecosystem
Biology: The Role of Fluorescent Ligands in GPCR Research GPCRs are one of the most important families of therapeutic Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic
- Tanishka S. Saraf | Dr. GPCR Ecosystem
Saraf " My research focuses on evaluating and targeting serotonin 1A receptors for therapeutic outcomes
- Fluorescent Probes for GLP-1R and GIPR Imaging: From Cell Assays to In Vivo Systems | Dr. GPCR Ecosystem
His work carries direct translational relevance to diabetes and obesity therapeutics. opportunities for scientists and biotech leaders working across pharmacology, translational research, and therapeutic
- how-to-build-breakthrough-gpcr-programs | Dr. GPCR Ecosystem
As co-founder and CEO of Keltic Pharma Therapeutics, he leads a biotechnology company developing a novel
- Dr. Jean-Philippe Pin | Dr. GPCR Ecosystem
biosensors, cryo-EM, photoswitchable ligands, and nanobodies as pharmacological tools and potential therapeutic
- Dr. Tore Bengtsson: Rethinking β₂-Adrenergic Signaling in Metabolic Disease | Dr. GPCR Ecosystem
Listeners gain insight into how basic GPCR pharmacology can translate into therapeutic strategies targeting He is also an entrepreneur and founder of biotechnology companies translating GPCR pharmacology into therapeutic GPCR signaling complexity and pathway selectivity Translating receptor pharmacology into metabolic therapeutics One is Sigrid Therapeutics, which focuses on digestion and metabolic regulation. That makes them unsuitable as long-term therapeutic drugs.
- the-spatiotemporal-revolution-in-gpcr-biology | Dr. GPCR Ecosystem
biologists, and drug discovery scientists working on GPCR systems where spatial organization influences therapeutic
- The Practical Assessment of Signaling Bias | Dr. GPCR Ecosystem
. 💊 Therapeutic Potential : Understanding bias enables researchers to design drugs that target specific Kenakin challenges the traditional approach and encourages leveraging bias for better therapeutic outcomes
- The Role of Quantitative Sciences in GPCRs with Dr. Nagarajan Vaidehi | Dr. GPCR Ecosystem
She has advanced the use of computational methods to meet the challenges of designing therapeutics with
- Dr. Brian Arey | Dr. GPCR Ecosystem
His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics
- Dr. Nicola J. Smith | Dr. GPCR Ecosystem
orphan GPCRs from ‘locked’, inaccessible receptors to well-characterized and understood ‘unlocked’ therapeutic
- Dr. Brian Arey | Dr. GPCR Ecosystem
His recently published book on signaling bias, Biased Signaling in Physiology, Pharmacology, and Therapeutics
- Dr. Andrew Tobin | Dr. GPCR Ecosystem
vehicle by which Andrew is translating fundamental findings to commercial products is Keltic Pharma Therapeutics
- Dr. Fiona Marshall: Three Decades Inside GPCR Drug Discovery | Dr. GPCR Ecosystem
thermostabilization strategy finally made GPCR structures routine, the insight that seeded Heptares Therapeutics She co-founded Heptares Therapeutics and served as Chief Scientific Officer for twelve years, through As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery
- Dr. Stephen Ferguson | Dr. GPCR Ecosystem
Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).
- Dr. Adriano Marchese | Dr. GPCR Ecosystem
The ultimate goal of Adriano’s research is to target novel aspects of GPCR signaling for therapeutic
- Dr. Kevin Pfleger | Dr. GPCR Ecosystem
Institute of Medical Research, Deputy Director of the Australian Research Council Centre for Personalised Therapeutics
- Irfan Dhanidina, Dr. Kathleen Caron and Dr. Lauren Slosky | Dr. GPCR Ecosystem
protein-coupled receptors (GPCRs) regulate motivated behavior and how these receptors can be targeted for therapeutic distinct signaling pathways with their physiological effects and may serve as the basis for more selective therapeutics
- Exploring Career Paths in GPCR Research with Dr. Jacek Mokrosiński | Dr. GPCR Ecosystem
Yamina will schedule a future talk with Jacek about GPCRs as therapeutic modalities. The discussion revealed their interest in GPCRs as therapeutic modalities and possible future collaborations
- Dr. Timo De Groof | Dr. GPCR Ecosystem
nanobodies as research tools, to investigate different GPCR conformations, while also focusing on their therapeutic
- Dr. Stephen Ferguson | Dr. GPCR Ecosystem
Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994).
- Dr. Michael Feigin | Dr. GPCR Ecosystem
Michael Feigin is an Associate Professor in the Department of Pharmacology and Therapeutics, and Director of Graduate Studies of Experimental Therapeutics at Roswell Park Comprehensive Cancer Center in Buffalo disrupting histone processing on rapidly proliferating cells, such as cancer cells, and suggested a therapeutic
- Dr. Prasenjit Saha | Dr. GPCR Ecosystem
receptors would be a significant breakthrough in cardiovascular biology as they could be targeted for therapeutic
- Visualizing GLP-1 & GIP Receptors in Islets and Brain | Dr. GPCR Ecosystem
neuronal circuits — insights that inform next-generation functional assay development and translational therapeutic
- Yamina's Corner | Dr. GPCR Ecosystem
Clear Platform Assessment: Gain rapid, independent insight into GPCR platform risks and true therapeutic Abishek Iyer, CEO Ashta Therapeutics Before working with Yamina, we had solid internal momentum but needed


























